Drug name - Victrelis

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602 MERCK SHARP DOHME Administration of HCV protease inhibitors in combination with food to improve bioavailability
Mar, 2027

(4 years from now)

US7772178 MERCK SHARP DOHME Pharmaceutical formulations and methods of treatment using the same
Nov, 2027

(4 years from now)

Drugs and Companies using BOCEPREVIR ingredient

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease


More Information on Dosage
Strength Dosage Availability
200MG CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.